Arizona State Retirement System Boosts Stock Position in Bristol Myers Squibb Company $BMY

Arizona State Retirement System raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 1.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 566,542 shares of the biopharmaceutical company’s stock after buying an additional 8,691 shares during the period. Arizona State Retirement System’s holdings in Bristol Myers Squibb were worth $32,644,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in BMY. Life Cycle Investment Partners Ltd purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth about $34,406,000. Lazard Asset Management LLC lifted its holdings in shares of Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after purchasing an additional 368,193 shares during the last quarter. Axxcess Wealth Management LLC boosted its position in shares of Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after purchasing an additional 21,196 shares during the period. Callan Family Office LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $3,575,000. Finally, BlackRock Inc. grew its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on BMY. Royal Bank Of Canada boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Raymond James Financial began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Citigroup reiterated a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a research note on Wednesday, August 5th. Finally, Guggenheim restated a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Stock Performance

Shares of BMY stock traded down $2.19 during midday trading on Tuesday, hitting $64.63. The company had a trading volume of 9,522,716 shares, compared to its average volume of 11,932,380. The company’s 50 day simple moving average is $63.09 and its 200 day simple moving average is $59.96. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The stock has a market cap of $132.02 billion, a price-to-earnings ratio of 14.24, a PEG ratio of 0.32 and a beta of 0.23. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter in the prior year, the business earned $1.46 earnings per share. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.